On March 23, 2026, Nicholas A. Saccomano, who serves as president and chief executive officer of OnKure Therapeutics, Inc. (NASDAQ: OKUR), sold 86 shares of the company’s Class A common stock. The disposition was executed at a weighted average price of $4.1565 per share, producing a total transaction value of $357. The individual trade prices ranged between $3.995 and $4.235.
The sale was not an open-market liquidity event by design but an automatic disposition to satisfy tax withholding obligations tied to the vesting of restricted stock units, according to a Form 4 filing submitted to the Securities and Exchange Commission. After the automatic sale, Saccomano directly holds 7,333 shares of OnKure Therapeutics.
InvestingPro data cited in company disclosures show the shares have experienced notable appreciation recently, with a 53% gain over the last six months and a 37% year-to-date increase. The timing of the transaction comes just days before the company’s scheduled earnings report on March 27.
In parallel to the insider transaction, investment bank H.C. Wainwright adjusted its valuation outlook for OnKure. The firm lowered its price target to $27 from a prior $34 while retaining a Buy rating. The analyst cited an anticipated equity raise in the second quarter of 2026 as the rationale for the lower target, indicating expectations for near-term funding activity.
OnKure’s clinical pipeline remains focused on its lead candidate, OKI-219, which is in Phase 1 testing as a mutant-selective PI3KαH1047R inhibitor intended for use in solid tumors. The ongoing trial status and the indicated need for future capital raise are described as part of the company’s strategic initiatives in regulatory filings and analyst commentary.
Context and implications - The CEO’s automatic sale was a tax-driven mechanics-related transaction rather than an explicit vote on company outlook. Investors will likely weigh the recent analyst adjustment and the prospect of an equity offering alongside upcoming quarterly results when assessing the stock.